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Association between 
Schistosomiasis mansoni and 
hepatitis C: systematic review
Associação entre esquistossomose 
mansônica e hepatite C: revisão 
sistemática
ABSTRACT
OBJECTIVE: To perform a systematic review of the prevalence of the 
HCV/S. mansoni co-infection and associated factors in Schistosoma 
mansoni-infected populations.
METHODS: The bibliographic search was carried out using the Medline, 
Lilacs, SciELO, Cochrane Library and Ibecs databases. The criteria for the 
studies’ selection and the extraction data were based on systematic review 
methods. Forty fi ve studies were found, with nine being excluded in a fi rst 
screening. Thirteen articles were used for data extraction.
RESULTS: The HCV infection rates in schistosomiasis populations range 
from 1% in Ethiopia to 50% in Egypt. Several studies had poorly defi ned 
methodologies, even in areas characterized by an association between 
hepatitis C and schistosomiasis, such as Brazil and Egypt, which meant 
conclusions were inconsistent. HCV infection rates in schistosomotic 
populations were heterogeneous and risk factors for acquiring the virus 
varied widely.
CONCLUSIONS: Despite the limitations, this review may help to identify 
regions with higher rates of hepatitis C and schistosomiasis association. 
However, more studies are necessary for the development of public health 
policies on prevention and control of both diseases.
DESCRIPTORS: Comorbidity. Hepatitis C, epidemiology. 
Schistosomiasis, epidemiology. Review.
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Schistosomiasis is the second most important parasitic 
infection after malaria and affects more than 200 million 
people in 74 countries.56 It is endemic, with high preva-
lence and morbidity rates in many countries, especially 
those in Africa, such as Egypt,18 Kenya9 and Sudan,27,44 
and in South America, mainly Brazil.38,a
The prevalence of schistosomiasis ranged from 15 to 
45% in Egypt and Brazil.18,38,a In this country, six to 
eight million people are infected with Schistosoma 
mansoni and about 30 million people live under risk of 
infection.a The prevalence of Schistosomiasis mansoni 
(SM) can reach up to 27% of the population in some 
areas of Northeastern Brazil,38 turning this country into 
a major schistosomiasis endemic area in the world.
The diverse clinical patterns observed for this 
disease depend on many factors, including parasite 
strain, host genetic background, host nutritional 
RESUMO
OBJETIVO: Realizar revisão sistemática sobre a prevalência da confecção do 
vírus da hepatite C e Schistosoma mansoni e os fatores de risco associados a 
indivíduos com esquistossomose.
MÉTODOS: Revisão realizada nas bases de dados Medline, Lilacs, SciELO, 
Biblioteca Cochrane e Ibecs. Os critérios de seleção e a obtenção dos dados 
foram baseados em métodos de revisão sistemática. Foram encontradas 45 
referências relevantes, das quais nove foram excluídas na primeira triagem, 
14 na leitura dos resumos e nove na leitura completa. Treze artigos foram 
selecionados para análise.
RESULTADOS: A prevalência da associação entre vírus da hepatite C e 
Schistosoma mansoni variou de 1% na Etiópia a 50% no Egito. Alguns estudos 
apresentam metodologias pouco defi nidas, mesmo em áreas caracterizadas 
pela associação entre vírus da hepatite C e S. mansoni, como Brasil e Egito, o 
que não permitiu conclusões consistentes. As taxas de infecção pelo VHC em 
populações esquistossomáticas foram heterogêneas e os fatores de risco para 
adquirir o vírus foram variáveis.
CONCLUSÕES: Apesar das limitações, esta análise pode ajudar a identifi car 
regiões com maiores taxas dessa associação. Outros estudos serão necessários 
para o desenvolvimento de políticas públicas de prevenção e controle dessas 
doenças.
DESCRITORES: Comorbidade. Hepatite C, epidemiologia. Esquistossomose, 
epidemiologia. Revisão.
INTRODUÇÃO
and immunological state, and co-infections.9,10,16,31,35 
Schistosomiasis may progress to the most advanced 
stage of disease, the hepatosplenic form (HS). This 
clinical form is observed in endemic areas and 
is characterized by portal hypertension that may 
cause digestive hemorrhage.28,42,48 When SM comes 
combined with other hepatic disease, especially the 
Hepatitis C Virus (HCV) infection, the progression 
of hepatic fi brosis into cirrhosis and hepatocellular 
carcinoma (HCC) can occur within a few years.29,40 
Concomitant SM and HCV infection is observed with 
high frequency in Egypt2,7,47 and Brazil.39
Hepatitis C is also considered an important public 
health issue throughout the world, with approximately 
3% of people (about 170 million) being infected with 
the HCV.1,2 It is also the most important cause of liver 
disease and HCC in developed countries, including the 
a Maciel RCR. Enzimas caniculares na forma hepatoesplênica da esquistossomose mansoni [dissertação de mestrado]. Recife: Universidade 
Federal de Pernambuco; 2006.
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United Kingdom and USA,5,41,53,54 and in developing 
countries, such as Egypt2,25,26 and Brazil.6,39,45
In Egypt, eight to ten million are infected and 68 million 
people have been exposed to HCV52 (a prevalence of 
10 to 60%), mainly in rural areas.15,17,21 The prevalence 
of HCV infection is lower in Brazil than in Egypt and 
varies from 2.5% to 4.9%, corresponding to approxi-
mately 3.9 to 7.6 million people.11
HCV may be implicated as a factor infl uencing the 
severity of schistosomiasis in developing countries. 
Likewise, an infl uence of SM on HCV severity has 
been suggested by some authors.29,33,39
There are many contradictory data about the prevalence 
of HCV/S. mansoni co-infection in SM endemic areas 
and the risk factors associated with increased suscep-
tibility for HCV infection in a S. mansoni-infected 
person, especially in the HS form.2,4,7,49
The worldwide relevance of the hepatitis C and schisto-
somiasis association as a public health issue is mainly 
due to the severe clinical patterns and high morbidity 
associated with it, especially in developing countries. 
This study aimed to perform a systematic review of 
the prevalence of the HCV/S. mansoni co-infection in 
SM-infected population living in endemic areas and 
associated factors.
METHODS
The bibliographic search was performed through a 
systematic search covering the 1990s and up to May 
2011. The terms “Schistosomiasis mansoni” and 
“Hepatitis C” were utilized to search the Medline, 
Lilacs, SciELO, Cochrane Library and IBECS data-
bases. These databases fulfi ll the minimum criteria 
search to conduct a systematic review, in accordance 
with the literature.22
Figure. Flowchart of the systematic review results of selected publications.
9 studies were excluded:
1 thesis
1 monograph
1 was in German language
1 used experimental model
2 repeated titles in different available




14 abstracts were excluded because did not 
prevalence of co-infection HCV/S. mansoni neither risk
 factor for HCV infection:
After complete reading
22 articles
13 articles were included in 
sistematic review
1 discussed immune response and genetic polymorphisms
1 was about apoptotic mechanisms in hepatic diseases
2 assessed biochemical markers
8 assessed citokyne patterns in immune response
2 discussed therapy and treatment progress in hepatitis C
1 did not discuss risk factors for acquire HCV infection1
2 did not measure the prevalence of co-infection25,34
In 1, the age of the majority subjects enrolled was less 
than 18 years old 49
4 used the serologic method for evaluate the S. mansoni
infection3,20,24,51
1 was a thesis resume50
9 articles were excluded:
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Forty-five publications were obtained through the 
website search described and a fi rst screening was 
performed. The criteria adopted for inclusion were:
• Studies in scientifi c article formats published on or 
after 1989, the year in which HCV was discovered;
• Titles published in English, Spanish or Portuguese 
with available abstracts;
• Studies performed with human populations.
Nine studies were excluded because they utilized expe-
rimental models, were presented as thesis or monograph 
or were redundant in different databases (Figure).
A second screening was done by analyzing the 36 
selected abstracts. Fourteen studies were excluded 
because they did not contain information about the 
prevalence of HCV/S. mansoni association or the risk 
factors associated with HCV infection in a schistoso-
miasis population (Figure).
A total of 22 articles were selected for complete 
reading. This step was carried out by a pair of 
reviewers where each one, independently, fi lled a table 
with the criteria relevant to the articles selected for 
data extraction.14,22 There was no discordance between 
the two reviewers in regard to the articles selected, 
with kappa index = 1 (p < 0.05). The inclusion criteria 
adopted in this step were:
• Population: subjects of both sexes infected by S. 
mansoni and living in endemic areas;
• Age group: > 18 years old;
• Measurement of HCV/S. mansoni association: 
studies that described the methods utilized to measure 
the prevalence of HCV and S. mansoni infections;
• Risk factors: studies that reported the risk factors 
associated with HCV infection and if there is a 
correlation with schistosomiasis.
Studies that used only serologic methods to evaluate 
the prevalence of S. mansoni infection were excluded 
because the distinction between past and present 
infection is not possible, raising doubts about the 
confi rmed SM diagnosis.20
Of the 22 articles selected for the last step, 13 fi lled all 
inclusion criteria and offered data required to analyze 
the prevalence of hepatitis C and schistosomiasis 
association in SM endemic areas. The exclusion of 
the nine articles in the last screening are described in 
Figure.1,3,20,24,25,34,49-51
RESULTS
Table 1, 2 and 3 list the 13 articles that were analyzed.
The prevalence of  HCV/S. mansoni association ranged 
from 0.837 to 50.0% among the studies, with the highest 
ranges in Egypt (10 to 50%).2,9,19,29,30
Among the 13 articles included in the fi nal step of the 
review, ten were cross-sectional studies,8,9,19,29,30,36,37,39,40,45 
one was a retrospective cases series,6 one was a pros-
pective cases series2 and the other was a cases series 
with an external control group.32 Five studies6,32,39,40,45 
were conducted in Brazil, fi ve in Egypt,2,9,19,29,30 two 
in Sudan,36,37 one in Ethiopia8 and one in Kenya.9 A 
higher prevalence of HCV infection was found in 
the SM population of Egypt, compared to the other 
countries (Table 1).
Eight studies2,6,19,32,36,37,40,45 sought to determine the sero-
logic prevalence of HCV infection in an SM population 
and one study proposed to verify any epidemiologic 
relationship of schistosomiasis and HBV and HCV sero-
logic markers.30 Six studies6,9,29,37,39,40 aimed to evaluate 
the severity of hepatic lesions and morbidity of hepatitis 
C when associated with SM and to correlate this with 
serologic markers. The mean age of humans enrolled in 
these studies was 33.7 years and in four articles subjects 
were > 40 years6,29,32,36 (Table 2).
The inclusion criteria used by the authors to choose 
subjects with schistosomiasis were mainly: people 
living in endemic areas with positive parasitological 
exams confi rmed by the presence of S. mansoni eggs 
in stool samples or rectal biopsies (eight studies) and/
or ultrasonography (US) compatible with periportal 
fibrosis (PPF) (six studies). The epidemiological 
history was considered in seven studies to compose 
diagnosis when in conjunction with one or both criteria 
mentioned above.
The main exclusion criteria adopted for the selected 
studies was if the person did not live at the study site. 
People with no history of contaminated water contact 
and/or with liver disease caused by alcohol consump-
tion, autoimmune disorders or by Hepatitis viruses A, 
B, D or with others etiologies were also excluded from 
these studies. Six studies did not mention the exclusion 
criteria adopted.2,9,19,30,32,36
The most commonly chosen technique of HCV diag-
nosis was 3rd generation anti-HCV ELISA, utilized 
in fi ve studies.8,9,36,37,45 Four other studies utilized 2nd 
generation anti-HCV ELISA.2,19,29,30 The quantifi cation 
of the viral titers was performed by HCV RNA PCR 
in seven studies.6,9,29,36,37,39,40
Six studies made appropriate epidemiologic and 
statistical analyses to confi rm the correlation between 
risk factors associated and HCV infection in SM 
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patients.19,29,32,36,37,40 The other articles suggested 
possible risk factors without any statistical correlation 
found (Table 3).
Blood transfusion was cited by seven of them as a risk 
factor for HCV contamination.2,6,29,32,39,40,45 The second 
most observed risk factor described in three studies was 
the antischistosomal mass treatment, due to the use of 
syringes and nosocomial equipments without proper steri-
lization.2,19,29 Surgical procedures,19,29 digestive endos-
copy,45 old age,9,19 genetic background9 and hemodialysis2 
were also cited as risk factors for HCV acquisition. Four 
studies did not fi nd any association between SM infection 
and an increased risk of acquiring HCV.8,30,36,37
DISCUSSION
Schistosomiasis is an important public health issue asso-
ciated with poverty and poor sanitary conditions.13 All 
studies described were conducted in developing countries 
since the 1970s, especially in Egypt, Sudan, Ethiopia, 
Kenya and Brazil, confi rming the impact of this disease 
in these countries.13 The association between schistoso-
miasis and hepatitis C has been studied by many authors, 
showing the importance of research into this condition 
worldwide (Tables 1, 2 and 3).
The majority of articles were cross-sectional studies 
(Table 1) and aimed to determine the prevalence of 
HCV infection in a confi rmed SM population. Cross-
sectional studies are important in identifying regions 
in developing countries that need more attention from 
the government authorities for the implementation 
of public health policies in regards to treatment and 
control for both hepatitis C and SM. On this point, 
this review may help to identify regions where the 
association of these diseases and the risk factors 
associated with HCV infection are relevant, and to aid 
the implementation of prevention and control actions.
Table 1. Authors, type of studies and their objectives.
Author Country Type of study Objective
Silva JLA et al45 (2008) Brazil Cross-sectional To obtain the serological prevalence for HCV in SM 
patients
Mudawi HM et al36,a (2007) Sudan Cross-sectional To determine the prevalence of HCV and identify 
the most common genotype in patients with HSS
Mudawi HM et al37,a (2007) Sudan Population based 
cross-sectional
To determine the HCV prevalence and the risk 
factors associated, in a population living in SM 
endemic area
Berthe N et al8 (2007) Ethiopia Population based 
cross-sectional
To elucidate determinants of morbidity in SM




To compare the severity of hepatic lesions and 
morbidity in co-infection in two populations with 
different epidemiological patterns for SM and 
hepatitis C
Pereira LMMB et al40,a 
(2001)
Brazil Cross-sectional with an 
external control group
To analyze the frequency of HBV and HCV markers 
and to correlate this with severity of hepatic lesions 
in co-infected patients
Kamal S et al29,a (2000) Egypt Cross-sectional To investigate the infl uence of SM on chronic 
hepatitis C with respect to the natural course of the 
disease and others parameters
Aquino RTR et al6 (2000) Brazil Retrospective cases 
series
To evaluate the frequency and the consequences 
of the co-infection of hepatitis B and C in patients 
with HSS
El-Sayed HF et al19,a (1997) Egypt Cross-sectional To determine the prevalence of HBV and HCV in a 
endemic area for SM and the risk factors associated 
with co-infection
Pereira LM et al39 (1995) Brazil Cross-sectional with an 
external control group
To investigate the HCV participation in severity of 
hepatic lesions in SM patients
Abdel-Wahab MF et al2 
(1994)
Egypt Prospective cases series To estimate the prevalence and magnitude of HCV 
infection in Egypt
Kamel MA et al30 (1994) Egypt Population based 
cross-sectional
To determine the epidemiological relationship 
between SM and HBV and HCV serologic markers
Lacerda CM et al32,a (1993) Brazil Cases series with an 
external control group
To study the HBV and HCV serologic markers in 50 
patients with HSS and compare the results with 50 
controls
a Authors used the logistic regression multivariate method to analyze the risk factors associated with HCV acquisition in an SM population.
HSS: Heaptocellular carcinoma; HCV: Hepatitis C Virus; SM: Shistosomiasis mansoni; HBV: Hepatitis B Virus
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Table 2. Systematic review of results of Hepatitis C Virus and Schistosoma mansoni diagnosis and prevalence of Hepatitis C 
Virus/ mansoni association.
Population size Population characteristics HCV diagnosis SM diagnosis Prevalence of Association
184 subjects45 41.3% male Anti-HCV ELISA 3rd 
generation
Not mentioned 11.9%
176 subjects36 81.3% male
Mean age = 41.4
Anti-HCV ELISA 3rd 
generation
HCV RNA PCR and 
genotype
Clinical and history 
examinations 
Ultrasonography (US) with 
periportal fi brosis (PPF)
4.5% for anti-HCV
2.3% for HCV RNA PCR
410 subjects37 45% male
Mean age = 35
91% have SM infection
Questionnaire
Anti-HCV ELISA 3rd 
generation
HCV RNA PCR














21-30 years old = 1.6%
31-40 = 0.8%
> 40 = 1%
237 Kenyans9
112 Egyptians
Mean age Kenyans: 33.1
Mean age Egyptians: 34















Presence of eggs in stools 
or rectal biopsy
20% for anti-HCV
12.4% for HCV RNA PCR
126 subjects29 84 men (66.6%)
Mean age = 43
Group A (n = 33): HCV 
infection; mean age = 
44.2
Group B (n = 30): 
Schistosomiasis; mean 
age = 38.2
Group C (n = 63): co-
infection; mean age = 
41.5
Anti-HCV ELISA 2nd 
generation
HCV RNA PCR
Presence of eggs in 







75.8% Caucasian; 8.1% 








506 subjects19 Mean age: 20
52% male; 48% female









SM: 43 with HIS
173 with HSS
115 male (53.4%)
Mean age = 38
Controls: 21 male (42%)






Presence of Schistosoma 




354 adults2 Patients admitted to Kasr 
El Aini Hospital, in Cairo, 
for chronic hepatic 
diseases evaluation
Liver function tests, 
liver biopsies
Anti-HCV ELISA 2nd 
generation







Mean age = 20.2 Anti-HCV ELISA 
2nd generation in 
duplicate samples
Kato-Katz






G 1: SM patients, 46% 
male; mean age = 41
G 2: 42% male; mean 
age = 44.4
Anti-HCV ELISA 1st 
generation
Medical records 20%
RT-PCR: real time – polymerase chain reaction; HCV: Hepatitis C Virus; SM: Schistosomiasis mansoni; HSS: Hepatosplenic 
schistosomiasis; HBV: Hepatitis B Virus; HCC: hepatocellular carcinoma; HIS: hepato intestinal schistosomiasis
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Table 3. Risk factors, results and conclusion of studies selected.
Risk factors for HCV Results Conclusion
Blood transfusion45
Digestive endoscopy
90.5% of co-infected had HSS form
54.5% received blood transfusion
Blood transfusion and endoscopy history 
are associated with the increase of HCV 
prevalence in HSS form.
No risk factor36,a Genotype 4 was the most prevalent in HS 
patients. The parenteral therapy was not 
associated with co-infection
The HCV prevalence in HS patients is 
considered low (4.5%) and the genotype 4 
is the most common in Sudan.
No risk factor37,a 91% had SM
11.2% had anti-HCV+, only 2.2% were HCV 
RNA PCR+
Between 21 and 40 years old, the anti-HCV 
reactivity was 7.8%
HCV infection has low prevalence in Sudan 
and the anti-SM parenteral therapy cannot 
be associated with co-infection.
No risk factor8 65.9% were positive for SM
1.3% subjects with SM were positive for HCV
The highest prevalence was found among 
children
It is necessary to integrate helminth control 
targeting school-aged children to reduce 
the risk of PPF in future.
Age older9
Genetic background
OPG mean was higher among the Kenyans than 
Egyptians
The PPF pattern was higher among Egyptians
Hepatitis C is 3 times more prevalent among 
Egyptians
Geographical differences are observed in 
relation to PPF patterns among the two 
populations. HCV is associated with active 
infection only among Egyptians, who 
present more severity and morbidity for 
co-infection.
Blood transfusion40,a 57% were positive for HBV or HCV or both HCV infection may contribute to severity 






The mortality in group C was 48% after 6 years 
in comparison with group A (12%) and B (3%). 
HCC is most frequent in co-infected (33%) 
patients than mono-infected. Mortality was not 
affected by age, HCV RNA titer or genotype 
virus
Patients co-infected are characterized 
by more advanced liver disease, higher 
HCV RNA titers, predominance of HCV 
genotype 4, higher infl ammatory activity, 
incidence of cirrhosis and HCC with much 
higher mortality rate.
Blood transfusion6 84.6% of anti-HCV+ had HCV RNA PCR+ 
with high aminotransferases, more cell 
decompensation and high rate of chronic 
hepatitis
The rate of hepatitis B and C markers in 
HSS patients is higher than control group 





Anti-HCV was positive in 10.3% of subjects and 
5% was positive for anti-HBV and anti-HCV
Hepatitis B and C are the major public 
health problems in Egypt. Studies about 
epidemiology, natural history, risk factors 
and modes of transmission are necessary.
No signifi cance between 
groups was found for 
blood transfusion39
The HCV prevalence in co-infected group was 
higher (22%) than in control group (2%).
61.7% of co-infected had HCV-RNA circulating 
with high levels of liver enzymes, especially in 
HSS decompensated form
Co-infection is a major factor contributing 
to the severity of liver disease in chronic 
SM and active replication of the virus in 
the liver or at extra-hepatic sites is strongly 





The prevalence of anti-HCV was 46% in renal 
chronic patients, 22.1% in soldiers and 47.2% 
in chronic hepatic diseases
HCV infection prevalence is high in Egypt, 
especially among patients with liver 
disorders. More studies are necessary to 
confi rm this transmission route.
No risk factors30 About 1550 samples examined by Kato-Katz 
technique, 49.1% were positive for SM.
The anti-HCV was + in 15,9%, and increases 
with age
No relationship among HBV or HCV and S. 
mansoni infection is found in those living 




Prevalence of HCV serologic marker was 20% 
in group 1 and 4% in group 2.
Among 10 HSS patients, 7 had received blood 
transfusion
A high prevalence for anti-HCV markers is 
found in SM patients in comparison with 
healthy people.
a Authors who used the logistic regression multivariate method to analyze the risk factors associated with Hepatitis C Virus 
acquisition in a Schistosomiasis mansoni population.
PCR: polymerase chain reaction; HCV: Hepatitis C Virus; SM: Schistosomiasis mansoni; HSS: Hepatosplenic schistosomiasis; 
HBV: Hepatitis B Vírus; HCC: hepatocellular carcinoma; HS: hepato schistosomiasis; PPF: periportal fi brosis; HSS: 
Hepatosplenic schistosomiasis
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A few studies pointed to a correlation between diseases 
with morbidity patterns, progression of liver damage29,39 
and risk factors2,6,9,19,29,30,36,37,39,40,45 in acquiring HCV. 
It could be useful to understand the clinical course 
of this particular condition and for treatment choices 
(Tables 2 and 3). When schistosomiasis and hepatitis 
C association is established, the clinical course deve-
lops into severe hepatocellular damage. Viral persis-
tence and hepatic cirrhosis can develop faster than in 
mono-infected people.6,29
The high percentage of HCV infection in schistoso-
miasis populations of different countries caught the 
attention of the scientifi c community for the variable 
prevalence of disease association rates.8,19,36,37,40,45 The 
rates ranged from 10 to 50% in Egypt,2,9,19,29,30 mainly 
due the mass treatment of the schistosomiasis infected 
population in the 1970s. This public policy was not 
adopted in other countries and similar prevalence rates 
cannot be observed.8,36,37 There is a lack of a relationship 
between the high prevalence of HCV infection in schis-
tosomiasis endemic areas and risk factors, although 
many of them were.
Disease association rates in Brazil, although not as 
high as in Egypt, can be considered relevant due to the 
high morbidity when HCV is present. When the study 
was conducted with hospital patients in Brazil, disease 
association rates were up to 20%.32,39,40 Confl icting 
results among studies on HCV/S. mansoni association 
in Brazil,6,40,45,46,b reinforce the need for further studies 
of this condition, especially with appropriate metho-
dologies for prevalence and risk factor evaluations. 
Methodological issues are the main problem of the 
majority of studies worldwide, suggesting the inade-
quacy of study designs.
The serologic method was the most commonly used 
method of evaluating HCV infections, including 
recently developed techniques adapted from the older 
versions. The 3rd generation ELISA is performed by 
many research groups, since it is a fast and relati-
vely cheap technique.8,9,36,37,45 Some authors reject 
this method because, in S. mansoni, infection could 
produce auto-antibodies against HCV epitopes, mimi-
cking HCV infection.3 However, this immunoglobulin 
(Ig) production is not well defi ned in the literature and 
the auto-Ig’s ratios are low, which can be differen-
tiated from HCV infection by increasing the cut-off 
point. As for schistosomiasis diagnosis, the method 
of choice continues being Kato-Katz test, based on 
the presence of S. mansoni eggs in stool samples or 
in rectal biopsies, and US patterns to evaluate the 
periportal fi brosis.43,55 This review confi rms that no 
signifi cant diagnosis methods have been developed for 
either disease over the last decades.
The current systematic review also considered risk 
factors associated with an increased chance of acquiring 
HCV infection when the subject has SM.19,29,32,36,37,40 
These data may be useful to direct monitoring and treat-
ment campaigns for both diseases and may contribute 
to lower prevalence and morbidity rates in the future.
Blood transfusion was the risk factor most cited6,32,39,40,45 
in Brazil and the anti-schistosomiasis parenteral mass 
therapy,2,19,29 in Egypt. Poorly sterilized syringes and 
equipment used during these campaigns21,26 may be the 
key to increased chances of acquiring HCV.
In the HS schistosomiasis form, common in endemic 
areas, the subject presents esophageal varices in most 
cases as a consequence of periportal hypertension and 
disease severity in SM.43 Disruption of these veins can 
cause digestive bleeding and blood transfusion may be 
required for patient survival.b
The serological screening in Brazilian blood banks did 
not include anti-HCV markers before 1993, in spite of the 
recent discovery of HCV. Blood transfusion before this 
year can be considered as a risk factor for HCV acquisi-
tion.12 The lack of proper sterilization of equipment and 
reused syringes during anti-schistosomiasis parenteral 
mass therapy21,23 increases the chance of HCV infection 
in SM patients in Egypt. The causes of HCV infection 
are different among the countries and in most cases the 
public policies are adopted as a refl ex.
In most articles, the risk factors were based on patient 
reports and epidemiological history, without signifi -
cant statistical analyses. More studies are needed to 
clarify HCV transmission routes and risk factors for 
HCV/S. mansoni association. The last study on this 
issue was published in 2008, pointing to the lack of 
research in this area.
In conclusion, this revision shows the lack of 
well-designed studies with appropriate methodology 
for evaluating the prevalence of this condition in areas 
of endemic schistosomiasis. Despite the limitations of 
this study, the results may help to identify regions with 
higher HCV/S. mansoni association rates. New public 
health policies attempting to reduce the current high 
prevalence and morbidity rates observed in hepatitis 
C and schistosomiasis could be proposed, especially 
in SM endemic regions.
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